For the planet, we aim for a positive footprint
for the planet
We are determined to make firm commitments to protect the planet
The climate emergency and environmental degradation incite us to adopt measures to reduce greenhouse gas emissions and bolster efforts to protect biodiversity and preserve natural resources. We adopt a comprehensive and integrated approach across the entire medicine value chain.
Our sense of responsibility drives us to take action. Quickly.
Taking tangible action to protect the climate
In response to the climate emergency, we are committed to reducing our greenhouse gas emissions.
We have already launched many initiatives at several of our facilities, for example to regenerate solvants, renovate buildings to enhance energy performance standards, purchase and generate renewable energy on site and develop sea freight as an alternative to air freight. As part of the partnership with EcoAct, we also offset a portion of our unavoidable residual emissions by funding carbon avoidance projects.
metric tons of CO2 equivalent were offset by Servier in 2022 through carbon avoidance projects
reduction in greenhouse gas emissions per box of medicines produced between 2016 and 2019
Positioning biodiversity at the heart of our CSR commitment
We once again underscored our commitment to protecting biodiversity when in 2021 we signed up to the Act4nature international initiative led by EpE (Entreprises pour l’Environnement).
Consequently, we comply with the 10 commitments set out by the intiative. We also took additional steps to:
We strive to achieve the highest standards at our future Research and Development Institute in Paris-Saclay:
At our R&D Institute at Paris-Saclay:
- 5,000 sqm of on-the-ground green spaces
- 9,000 sqm of green roofs
- 100 sqm of community gardens
- Over 70 plant species
Harnessing eco-design for medicine to bring about sustainable and responsible innovation
We make firm commitments with respect to the impact of our operations on society and the environment. We do so all throughout the medicine life cycle through our EcoDesign by Servier program.
To develop the road map for the program, we used life cycle analysis methodology to assess the environmental aspects of medicines—i.e., through the design, extraction of raw materials, production, distribution, usage and end-of-life disposal.
The program helps to take better account of social and environmental considerations such as climate change, biodiversity and natural resources, in accordance with efficacy and therapeutic safety requirements.
We have also developed the “Green Score” system for use within the Group, which integrates the principles of sustainable chemistry, including ecotoxicity and climate impact. By 2023, 100% of new chemical syntheses will be given a Green Score.
Target set for EcoDesign by Servier
We pledge to integrate eco-design principles to packaging for new brand-name medicines, in accordance with pharmaceutical regulations, between now and 2025.
 Scope 1 emissions represent emissions directly linked to Group operations. Scope 2 emissions are linked to the purchase of electricity and energy for heating or cooling.
 Scope 3 emissions include all other indirect emissions, throughout the value chain (procurement, transport, business travel, etc.).